Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.

Trial Details

NCT ID

NCT07070466

Phase

PHASE2

Sponsor

Massachusetts General Hospital

Status

RECRUITING

Cancer Type

Adenocarcinoma Esophageal Cancer

Interventions

Ivonescimab
5-Fluorouracil
Oxaliplatin
Leucovorin

Locations (sample)

Santa Monica, California, United States|34.01949,-118.49138
Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Patients must have a pathologically confirmed diagnosis of adenocarcinoma of the esophagus, gastroesophageal junction, stomach. Squamous cell tumor…
Participants must have disease that can be evaluated radiographically. This includes disease that may be measurable or non-measurable as per RECIST…
Patients may not have received prior therapy for Stage IV disease. Patients may have received prior adjuvant therapy if more than 6 months have ela…
Age ≥18 years old. Because there is no dosing or adverse event data for ivonescimab with FOLFOX in participants \<18 years of age, children are exc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →